Source: Eur Respir J 2016; 48: 1320-1328
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Guillaume Lezmi, Louise Galmiche-Rolland, Sabine Rioux, Francis Jaubert, Isabelle Tillie-Leblond, Pierre Scheinmann, Philippe Gosset and Jacques de Blic. Mast cells are associated with exacerbations and eosinophilia in children with severe asthma. Eur Respir J 2016; 48: 1320-1328

Member's Comments

No comment yet.

Related content which might interest you: Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Factors driving airway eosinophilia in prednisone-dependent severe asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020 Role of neutrophils in airway inflammation in children with severe persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Benralizumab for severe asthma associated with extra-airway eosinophilic diseases Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Neutrophilic inflammation in severe asthmatics and COPD patients with the same severity of airway obstruction Source: Eur Respir J 2002; 20: Suppl. 38, 505s Year: 2002 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Predictors of sputum eosinophilia in severe asthma Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Gamma/delta T cells regulate airways disease during rhinovirus-induced asthma exacerbations Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections Year: 2011 Mast cell subtypes in adults and children with severe asthma Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 The prevention of virus-induced exacerbation of bronchial asthma in children Source: Annual Congress 2012 - Treating childhood asthma Year: 2012 Persistent airway inflammation in young allergic wheezing children treated with inhaled corticosteroids Source: Annual Congress 2003 - Current issues on wheezing in infancy Year: 2003 Treatment of bronchial asthma and wheezing disorders: chronic Source: ERS Skills Course 2016 Year: 2016